Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolf-Dieter Ludwig

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Der Internist|March 13, 2019
[Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges]Wolf-Dieter Ludwig
Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology|November 6, 2004
Minimal residual disease detection by flow cytometryWolf-Dieter Ludwig
Pneumologie (Stuttgart, Germany)|September 19, 2009
[Interview -- drug legislation -- reporting unexpected adverse drug reactions]Wolf-Dieter Ludwig
Aktuelle Urologie|July 25, 2007
[Editorial comment on Krege S. et al: off-label use: an unsolved problem]Wolf-Dieter Ludwig
Zeitschrift Fur Arztliche Fortbildung Und Qualitatssicherung|June 17, 2005
[Legal aspects of medication prescription]Wolf-Dieter Ludwig
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|February 14, 2012
[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]Wolf-Dieter Ludwig
Onkologie|October 8, 2010
[Open questions in the drug therapy of tumors with new active substances]Wolf-Dieter Ludwig, Gisela Schott
Onkologie|March 11, 2011
[Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies]Wolf-Dieter Ludwig, Jan Schildmann
Onkologie|April 4, 2013
[New drugs in oncology--features of clinical trials for market authorisation and arguments for the rapid implementation of independent clinical trials following approval]Wolf-Dieter Ludwig, Gisela Schott
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|February 14, 2009
[Improving drug safety in Germany: an alliance between the government and the medical profession]Bruno Müller-Oerlinghausen, Wolf-Dieter Ludwig
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Der Internist|March 13, 2019
[Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges]Wolf-Dieter Ludwig
Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology|November 6, 2004
Minimal residual disease detection by flow cytometryWolf-Dieter Ludwig
Pneumologie (Stuttgart, Germany)|September 19, 2009
[Interview -- drug legislation -- reporting unexpected adverse drug reactions]Wolf-Dieter Ludwig
Aktuelle Urologie|July 25, 2007
[Editorial comment on Krege S. et al: off-label use: an unsolved problem]Wolf-Dieter Ludwig
Zeitschrift Fur Arztliche Fortbildung Und Qualitatssicherung|June 17, 2005
[Legal aspects of medication prescription]Wolf-Dieter Ludwig
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|February 14, 2012
[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]Wolf-Dieter Ludwig
Onkologie|October 8, 2010
[Open questions in the drug therapy of tumors with new active substances]Wolf-Dieter Ludwig, Gisela Schott
Onkologie|March 11, 2011
[Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies]Wolf-Dieter Ludwig, Jan Schildmann
Onkologie|April 4, 2013
[New drugs in oncology--features of clinical trials for market authorisation and arguments for the rapid implementation of independent clinical trials following approval]Wolf-Dieter Ludwig, Gisela Schott
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|February 14, 2009
[Improving drug safety in Germany: an alliance between the government and the medical profession]Bruno Müller-Oerlinghausen, Wolf-Dieter Ludwig
Pageof 12